



10/04/00

Transmittal Letter to the United States
Designated/Elected Office (DO/EO/US)

525 Rec'd PCT/PTO 04 OCT 2000

09/647882

Page 1

Prepared from
FORM PTO-1390

Attorney's Docket No. : A20-015
U.S. Application No. : Not yet assigned
International Application No. : PCT/AU99/00273
International Filing Date. : 14 April 1999 (14.04.99)
Priority Date Claimed : 14 April 1998 (14.04.98)
Title of Invention : Food Supplement
Applicant(s) for (DO/EO/US) : Food Ingredients Technologies Intangibles (Ber muda) Limited

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures [35 U.S.C. 371 (f)] at any time rather than delay examination until the expiration of the applicable time limit set forth in 35 U.S.C 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed [35 U.S.C. 371(c)(2)]
 - a) ☒ is transmitted herewith (required only if not transmitted by the International Bureau)
 - b) ☐ has been transmitted by the international Bureau
 - c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English [35 U.S.C.371(c)(2)]
7. ☐ Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C.371(c)(3)]
 - a) ☐ are transmitted herewith (required only if not transmitted by the International Bureau)
 - b) ☐ have been transmitted by the International Bureau
 - c) ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
 - d) ☐ have not been made and will not be made
8. ☐ A translation of the amendments to the claims under PCT Article 19 [35 U.S.C.371(c)(3)]
9. ☒ An oath or declaration of the inventor(s) [35 U.S.C.371(c)(4)]
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 [35 U.S.C.371(c)(5)]

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98
12. ☒ An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included
13. ☒ A **FIRST** preliminary amendment
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment
14. ☐ A substitute specification
15. ☐ A change of power of attorney and/or address letter
16. ☒ (other items or information) PCT Publication WO 99/52381; Amendment Made Under Article 34; Form PCT/RO/101; Form PCT/IB/308; Form PCT/IB/332; Form PCT/IPEA/401; Form PCT/IPEA/409; and a Power of Attorney.

EXPRESS MAIL No.: EL 360 627 855 US Deposited: October 4, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service Express mail under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Helen Tam

October 4, 2000
Date

17. X The following fees are submitted:

		CALCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE [37 CFR 1.492(a)(1)-(5)]:			
Search Report has been prepared by the EPO or JPO	\$ 840.00		
International preliminary examination fee paid to USPTO [37 CFR 1.482]	\$ 670.00		
No International preliminary examination fee paid to USPTO [37 CFR 1.482] but International search fee paid to USPTO [37 CFR 1.445(a)(2)]	\$ 690.00		
<u>X</u> Neither International preliminary examination fee [37 CFR 1.482] nor International search fee [37 CFR 1.445(a)(2)] paid to USPTO	\$ 970.00	970.00	
International preliminary examination fee paid to USPTO [37 CFR 1.482] and all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 96.00		
ENTER APPROPRIATE BASIC FEE AMOUNT		\$ 970.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>X</u> 20 <u> </u> 30 months from the earliest claimed priority date [37 CFR 1.492(e)]		\$ 130.00	
Claims	Number filed	Number extra	Rate
Total Claims (Prel.Amd)	39 -20=	19 x	\$ 18. =
Indep. Claims	3 - 3=	0 x	\$ 78. =
Multiple Dependent Claim(s) (if applicable) + \$ 260. =			\$
TOTAL OF ABOVE CALCULATIONS =		\$1442.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must be filed. [Note 37 CFR 1.9, 1.27, 1.28]			
SUBTOTAL =		\$ 721.00	
Processing fee of \$130.00 for furnishing the English Translation later than <u> </u> 20 <u> </u> 30 months from the earliest claimed priority date [37 CFR 1.492(f)]		\$	
TOTAL NATIONAL FEE =		\$	
Fee for recording the enclosed assignment [37 CFR 1.21(h)] The assignment must be accompanied by an appropriate cover sheet [37 CFR 3.28, 3.31]. \$40.00 per property		\$ 40.00	
TOTAL FEES ENCLOSED =		\$ 761.00	
(AMOUNTS TO BE REFUNDED OR CHARGED)		REFUNDED \$	
		CHARGED \$	

a) ✓ A check in the amount of **\$761.00** to cover the above fees is enclosed.

b) Please charge my Deposit Account No. **04-0838** in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.

c) ✓ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **04-0838**. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 36 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Henry D. Coleman, Esq.
Coleman Sudol Sapone, P.C.
708 Third Avenue, 14th Floor
New York, NY 10017
Tel. (212) 679-0090

Henry D. Coleman
Name

signature

32,559
Reg. No.

October 4, 2000
Date

Applicant: FOOD INGREDIENTS TECHNOLOGIES
INTANGIBLES (BERMUDA) LIMITED

Clarendon House, Church Street, Hamilton, Bermuda

Serial No.: N/A

Filed: 14th April 1998

For: Food Supplement

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
SMALL BUSINESS CONCERN

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: FOOD INGREDIENTS TECHNOLOGIES
INTANGIBLES (BERMUDA) LIMITED

ADDRESS OF CONCERN: Clarendon House, Church Street, Hamilton, Bermuda

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed, to and remain with the small business concern identified above with regard to the invention, entitled: FOOD SUPPLEMENT by Inventors Timothy LANG, Derek DENTON, Anthony R BIRD and David TOPPING described in the specification filed herewith.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(c) or by any concern which would not qualify

as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME:

ADDRESS:

INDIVIDUAL

SMALL BUSINESS CONCERN

NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28 (b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such wilful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

GRAHAM CHARLES NOTTLE

TITLE OF PERSON OTHER THAN OWNER:

MANAGING DIRECTOR

ADDRESS OF PERSON SIGNING:

44 KENS RD FRENCHS FOREST
NSW 2086

SIGNATURE:



DATE: 31 AUGUST 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : FOOD INGREDIENTS TECHNOLOGIES INTANGIBLES
(BERMUDA) LIMITED

Serial No. : NYA (U.S. National Phase of Int'l Appln. No. PCT/AU99/00273)

Filed : Herewith

For : Food Supplement

Commissioner for Patents
Washington, D.C. 20231

Preliminary Amendment

S I R:

The above referenced U.S. National Phase of International Application PCT/AU99/00273 is submitted herewith. Applicant respectfully requests the United States application be amended as follows:

IN THE CLAIMS:

Please amend the claims as follow:


In claim 18, change "any one of claims 1 to 17" to --claim 1--;

In claim 28, change "one of claims 25 or 27" to --claim 25--.

Remarks

This amendment is submitted to remove any multiple dependency which may have existed in the corresponding PCT application. This amendment is submitted prior to the calculation of the basic filing fee and in anticipation of a first office action.

Respectfully submitted,
COLEMAN SUDOL SAPONE, P.C.

By: 
Henry D. Coleman
Reg No. 32,559

HDC: ht
708 Third Avenue, 14th Floor
New York, New York 10017
(212) 679-0090

Date: September 29, 2000

ART 34 AMDT

09/647882

1

FOOD SUPPLEMENT

This invention relates to a food supplement, derived from fruit or vegetable fibres, which has beneficial effects for bowel health.

5

BACKGROUND OF THE INVENTION

Short Chain Fatty Acids (SCFA's) are known to have significant physiological effects on the large bowel. In particular, SCFA's are considered to play a role in the protection against bowel cancer and the development of pathogenic organisms and the development of colonic ulceration and other diseases of the bowel.

10

SCFA's (acetate, propionate and butyrate) are produced in the large bowel by microbial fermentation. The benefits attributed to these compounds are variously thought to be the result of either reduced pH or beneficial changes to the molar ratios of acetate, propionate and butyrate or some combination of these. The concentration of SCFA's, pH and in particular butyrate concentration are putative indicators of bowel health.

15

More particularly, butyrate is considered to offer protection against bowel cancer. As most intestinal cancers occur in the distal colon, an increased level of butyrate in this region is a key objective in controlling the incidence and development of this type of cancer.

20

In the processing of fruit and vegetable for consumption, a considerable amount of the fruit or vegetable remains unused because it is either unpalatable or inconvenient to use. This represents a somewhat inefficient use of resources and leads to a waste disposal problem and a loss of potentially valuable resources.

25

It is also desirable to have a fibre additive for foods that is a substitute, or a partial substitute for ingredients of commonly used foods substances such as flour in bread. Also desired is that these substitutes do not add to the calorific content of the foods, and in many instances that these substitutes do either not contribute flavours at all or at least do not contribute off flavours. A number of examples of fibre food additives are made from waste from fruit or vegetable processing, and one such example is the use of treated citrus albedo for inclusion of a flour substitute in various cereal products such as bread in US patent No 4526794 by Altomare et al.

35

DISCLOSURE OF THE INVENTION

It is a finding of this invention that the use of a mixture of fibre extracts from two or more types of fruit or vegetables can have a beneficial effect on the large bowel.

ART 34 AMDT

Fibre extracts from apple slices and from the albedo of oranges were extracted by a counter current method and added as a supplement to a standard feed for pigs and to a diet for humans. An unexpected beneficial change in indicators of gut health was found when
5 mixtures of the two fibre extracts were used when compared to the use of each fibre extract separately.

The effect is manifest in an increased production of short chain fatty acids in the large bowel, of which butyrate is the fatty acid that is increased to the greatest degree particularly
10 in the distal colon. The experiments conducted to date are suggestive that the physiology of the large intestine is also somewhat modified in so far as the wall of the large intestine is thickened albeit by a statistically not significant amount, indicating that there may be stimulation of growth.

15 The term fibre in the context of this invention is intended to convey the meaning of material that is substantially indigestible in the small intestine such that it passes into the large bowel of a human or other omnivorous animal species.

It is thus proposed that in a broad form that the present invention could be said to reside in
20 a food supplement, said food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom.

At present the reason why such combinations of fibre extracts exert their effect is
25 unknown, it is however thought that removal of a majority of the soluble solids is essential for this to have effect. One hypothesis is that insoluble fibre components presented in this way have a more beneficial action in promoting colonisation of beneficial bacteria in the large intestine, thereby acting as a prebiotic.

30 The removal of soluble solids also has the side benefit of maximising the potential value obtained from the precursor product in so far as it may be possible to sell some or all of the soluble solids. Additionally the insoluble solids that remain are more convenient for food use because they may be dried and hence put into a wider range of foods than would be possible with soluble materials. Insoluble solids from which soluble solids have been
35 removed also have a tendency to be more stable microbiologically and not to produce off flavours, there is also the possibility that any anti microbial substances (that might otherwise adversely affect beneficial large bowel microflora) present in parts of the fruit are also removed.

The two or more types of fruit or vegetable may be selected from the group consisting of grape, citrus, apple, tomato, carrot, mango, papaya, banana, pineapple, kiwi fruit, spinach and melon.

5

Preferably the two or more types of fruit or vegetables are selected from the group consisting of, grape, orange, apple, tomato, melon, cranberry and grapefruit.

10 In an alternative form a first of the two or more fruit and vegetables is a citrus fruit and a second fruit is selected from the group consisting of grape, apple, tomato, carrot, mango, papaya, banana, pineapple, kiwi fruit, spinach, melon and cranberry and more preferably the second fruit is selected from the group consisting of grape, apple, tomato, melon and cranberry. In one convenient form the citrus fruit is an orange.

15 In another alternative form a first of the two or more fruit and vegetables is an apple, and a second fruit is selected from the group consisting of grape, citrus, tomato, carrot, mango, papaya, banana, pineapple, kiwi fruit, spinach, a melon, and more preferably the second fruit is selected from the group consisting of grape, citrus, tomato, and melon.

20 In one specific form the fibre extracts from two fruits are used, the two fruits being orange and apple.

Citrus fruits that might be used including orange, grapefruit, tangelo, tangerine, lemon, kinnow fruit and varieties. When dealing with citrus by product parts, citrus "cups" can be used. Cups are halves of the outer portion of citrus fruits comprising the skin (flavedo) and the pith (albedo) and represent the portion of citrus fruit remaining after conventional juice extraction. Preferably the starting material for fibre extraction is a shaved skin, whereby the flavedo has been removed. The benefit of using albedo is that processing is simplified, so that the strongly flavoured portion of the skin is not included.

30

For pineapples, the "zenith" solids, which comprise the outer skin and inner core of pineapple can be used. Also whole pineapples can be used.

35 When papaya is the precursor just the flesh and skin are to be processed. When the seed is included the resultant product has a higher fibre content. Likewise mangos, without seed can be processed.

When a melon is used it might be selected from the group consisting of watermelon, rock melon, honeydew melon or champagne melon.

Without being bound by the same, a possible explanation for the beneficial effects of the combinations of fibre extracts is that the two fibre components each offer different levels of minerals, neutral non starch polysaccharides and uronic acids and that a synergy is afforded by a combination of fruits or vegetables having the different levels. Soluble and insoluble neutral non starch polysaccharides, and soluble and insoluble uronic acids provide four possible substrates for microbial growth in the colon. These four possible substrates may result in a series of microbial populations being established along the large bowel, each acclimatised to a preferred substrate and each producing different SCFA's. In this way, the varying molar ratios of the individual SCFA's may be explained.

The high level of calcium and other elements are considered to provide beneficial effects on the proliferation of colon cells, the excretion of bile acids and avoiding mineral losses from occurring, for example with diarrhoea. Thus in the case of a mixture of orange and apple fibres, it has been determined that orange is higher in calcium, soluble neutral non starch polysaccharides and total uronic acids than is the apple. Thus it may be expected that the combination of a first fruit or vegetable having levels of one or more mineral or fibre components that are similar to orange and a second fruit or vegetable having levels comparable to apple may provide the synergistic effect. Some typical compositions of fruits are given in Table 1.

Thus in one embodiment of the invention the invention may be said to reside in a food supplement, said food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom and wherein a first of the two or more fruits or vegetables has :

- a calcium content of between 4000 and 15000 ppm;
 - a soluble neutral non starch polysaccharides content of between 2 and 3 percent dry weight; and
 - a total uronic acids content of between 20 and 40 percent dry weight
- and the second of the two or more fruit or vegetables has :
- a calcium content of between 200 and 1500 ppm;
 - a soluble neutral non starch polysaccharides content of between 1 and 2 percent dry weight; and
 - a total uronic acids content of between 5 and 20 percent dry weight.

ART 34 AMDT

Alternatively the invention may be said to reside in a food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom and wherein a first of the two or more fruits or vegetables has a calcium content of between 4000 and 15000 ppm and a second of the
5 two or more fruit or vegetables has a calcium content of between 200 and 1500 ppm.

Alternatively still the invention may be said to reside in a food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom and wherein a first of the two or more fruits
10 or vegetables has a soluble neutral non starch polysaccharide content of between 2 and 3 percent dry weight and a second of the two or more fruit or vegetables has a soluble neutral non starch polysaccharides content of between 1 and 2 percent dry weight.

As a further alternative the invention may be said to reside in a food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom and wherein a first of the two or more
15 fruits or vegetables has a total uronic acids content of between 20 and 40 percent dry weight and a second of the two or more fruit or vegetables has a total uronic acids content of between 5 and 20 percent dry weight.

Preferably the ratio of the first fibre extract to the second fibre extract in the food supplement is between 1:4 and 4:1 and is most preferably between 2:3 to 3:2. In one preferred from of the invention the two fibre extracts are present in equal amounts by
20 weight.

The invention may also be said to reside in a method of preparing a food supplement derived from fibre extracts from two or more types of fruit or vegetables, the method including the steps of removing a majority of the soluble solids from each of the two or more types of fruit or vegetables separately to give fibre extracts from the two or more
30 fruits or vegetables, and combining the fibre extracts to provide the food supplement.

The method may include the steps of slicing each of the two or more fruits or vegetables into substantially uniform pieces, and substantially removing any remaining seed tissue from the fibre extracts after extraction an then combining the fibre extracts to provide the
35 food supplement.

The method may also include the steps of inactivating enzymes within the fruit or vegetable pieces.

ART 34 AMDT

The precursor material is preferably undigested, in the sense that it has not been macerated, or treated enzymically, or by other chemical agents such as acid or alkaline to breakdown the structure of the macromolecules forming the fibres. The structure of the plant material is thus still complex. Thus when an apple is prepared for conventional pressing it is first milled, a process in which almost all of the cell walls are disrupted and in fact compounds normally isolated in cell walls or cytoplasm or vacuoles, nuclei etc are homogenised and begin to react. Many of these reactions are enzymically driven such as depolymerisation of pectin or oxidation. On the other hand when an apple is prepared by a preferred embodiment of this invention the apple is sliced, so that the longest diffusion path is no more than say 1.5mm. Slicing disrupts only a small proportion of cell walls, perhaps 0.5%, and the enzymes and their substrates are kept separate.

The method of preparing fibre also preferably includes the step of inactivating enzymes within the fruit preparation which might conveniently be by heat inactivation. Thus with the example of apple slices after slicing the slices are flash heated to a temperature at which plasmolysis occurs but no heat damage occurs to flavour compounds (60°C). This is termed a critical temperature. The resultant increase in permeability of the (still intact) cell wall increases significantly the rate of transfer of soluble solids from solid to liquid phase.

The majority of soluble solids are then removed from the precursor, by extracting liquids. This is achieved by preparing the precursor material to an appropriate size, for example by slicing to a particle with a thickness of no more than about 2 to 3 mm is found optimal for apple slices, and precontacting the precursor food material with an extraction liquid, and then separating the precursor food material from the extraction liquid, the separation occurring to an extent to give the desired reduction in soluble solids.

This extraction liquid is most preferably water, however, a non-aqueous or non-polar solvent might be used to extract water-insoluble or non-polar compounds. Examples of such solvents are, chloroform, hexane, chlorinated hydrocarbons or acetone. A specific example is the extraction of isoflavones and other flavanoids from orange peel using ethanol as the solvent.

It is preferred that water soluble solids are substantially all removed, in which case the fibre product is substantially free of sugars and other very readily soluble solids whereby greater than 90% of soluble solids are removed. One effect of this is that the fibre product is stabilised against microbial attack. That is not to say that microbial degradation of the

ART 34 AMDT

fibre is totally inhibited, but rather that this is reduced. Generally fungal growth is not inhibited but growth of the more common food spoiling bacteria are.

5 Additionally by removal of substantially all of the soluble solids the fibre product has a reduced potential for the development of an off taste, because compounds responsible for flavours have been extracted by the extraction process. Removal of substantially all of the soluble solids is intended to mean removal of substantially all soluble solids that are in a free or unbound state.

10 A processor suitable for extraction by counter current methods is described in Australian Patent No. 543184. Alternatively other extraction apparatus that could be used include a diffuser made by DeDanske Sukkerfabriker of Denmark and a diffuser made by Amos of Germany. It is anticipated that by use of these processes greater than 90% of the water soluble solids are removed, and more preferably from between 93 to 99%.

15 The benefits of the invention are expected largely to result by reason of fermentation in the large bowel of non-digestible components of the fruits outlined above, and it is anticipated that less purified forms of the fibres will also have a similar effect to that found for the more purified forms of fibre. It is however not desirable to use conventional techniques of
20 expressing juice from fruit because the supplement will be high in flavours, sugars, and acids. The material is unstable microbiologically and enzymatically and will rapidly develop off flavours and odours and will quickly discolour.

In another form the invention may be said to reside in agent for increasing levels of one or
25 more fatty acids to the colon of an animal or human wherein the agent is derived from fibre extracts from two or more types of fruit or vegetables that have had a majority of soluble solids removed therefrom. Preferably the increased level of fatty acids is greater than the level afforded by any one of the fruits or vegetables alone. Preferably also the fatty acid is a short chain fatty acid which may include acetate, propionate and butyrate. The one or
30 more types of fruit and vegetables may be selected from the group described herein.

It will be appreciated that the invention could also reside in a food product having the food supplement. Suitable food products that may contain the food supplement include, but are not limited to, breakfast cereals, granola bars, soups and beverages including fruit juices.

35 Preferably the food product contains between 1 and 50 % by weight of the food supplement and most preferably between 1 and 30%. In the case of liquid food products the upper limit to the amount of fibre supplement that may be added is determined by the viscosity of the ensuing product. Thus, preferably soups may contain between 2 and 15%

of the food supplement and beverages may contain between 2 and 5 % of the food supplement.

- For a better understanding the invention will now be described with reference to a number of examples. It is understood that these examples are only illustrative and are not intended to limit the scope of the invention.

DETAILED DESCRIPTION OF EXAMPLES OF THE INVENTION.

10 PREPARATION OF APPLE FIBRE EXTRACT

Preparation

The apples were of the Granny Smith variety from Batlow in New South Wales, Australia, and were in good condition. Apples were prepared by slicing to a 2mm thickness with a crinkle cut to provide better structural integrity.

15

The Counter Current Extractor (CCE)

- A counter current juice extractor available from FITA of Sydney Australia was used. The method of extracting juice from fruit and vegetables using this machine is described in Australia Patent No 543184. The CCE was set up with an angle of 4.5° a short cycle time of approximately 17 seconds, a residence time of about 1 hour. Oxidation was minimal at the temperature settings recorded.

20

The CCE was set up with the following operation conditions:-

- | | | |
|----|--------------------------|-------------------------|
| 25 | • feed rate | 12 kg/hr |
| | • extraction water | 15 kg/hr |
| | • angle | 4.5° |
| | • cycle time | 17 seconds |
| | • TF time forward | 9.5 sec |
| 30 | • TR time reverse | 7.2 sec |
| | • RPM | 3 |
| | • Temperature at recycle | 63°C |
| | • Residence time | 60 minutes |
| | • Preparation | 2mm slice (Crinkle cut) |
| 35 | • Pool level | low |

Apples fed to the CCE via the slicer in 1 kg quantities at 5 minute intervals.

ART 34 AMDT

Extracted slices were recovered from the CCE in thoroughly cleaned plastic containers for further processing. Juice was recovered at a temperature of 18°C covered stainless steel buckets for further processing.

5 Fibre recovery

The fibre emerging from the CCE was collected and held for a period of about 4 hours then milled using a Fitzmill with 1/2 inch screen. This was to minimise damage to seed and skin tissue.

- 10 The fibre was then put through a paddle finisher to remove skin and seed tissue using a 40 thousandth of an inch screen where skin and seed tissue were removed. No attempt was made to dewater the fibre from this trial. When preparing fibre samples for feeding trials the seed tissue was removed but the skin tissue was not removed.

- 15 The resultant fibre was relatively free of seed tissue. The yield of fibre emerging from the CCE represented 90% of the mass of the apples entering the process. The balance (10%) represented the soluble solids extracted by diffusion.

Samples of the fibre were dried in an oven the results indicating that there was a recovery of 4.0 to 4.5% of the mass of the apples as dried fibre.

- 25 The quality of the fibre, organoleptically, was good being of pale colour and with no propensity to oxidize. It had only a very slight taste of apple which disappeared on drying, it was highly viscous (approximately 3 cm Bostwick) with strong water binding capacity.

Cleaned fibre was packed in heavy duty plastic bags in approximately 10kg quantities with a maximum thickness of 6cm. These packages were then stored at -20°C.

- 30 Yield of soluble solids in juice 92.9%. It should be noted that in commercial operation the extracted slices will be pressed to remove half their weight as water and this water (or dilute juice) is returned to the CCE as extraction liquor. Therefore yield equivalent is 96.5%. There was no evident browning of the fibre or juice emerging from the machine.

35 PREPARATION OF ORANGE FIBRE EXTRACT

Preparation

The peel used for this trial was from early season Valencia oranges grown in Berri in the Upper Murray district of South Australia.

- Orange albedo was prepared in the following way at the Berri Fruit Juice plant at Berri, South Australia. Peel was returned from brown reamers to brown shavers where a gross separation of Albedo and Flavedo was effected. The separation was imperfect with the
- 5 Albedo containing approximately 15% flavedo tissue. The two sections of peel from the shavers was packed into cardboard boxes each containing 10kg. Boxes of Flavedo and Albedo were then frozen to -20°C and transported to Sydney. Before feed to the CCE the Albedo tissue was thawed, further hand sorted to remove as much flavedo as possible and hand cut to reduce particle size (nominally 20mm x 3mm thick) using a knife.

10

CCE operation

The CCE was set up with the following operation conditions

- | | | |
|----|--------------------------|--------------|
| | • feed rate | 12 kg/hr |
| 15 | • extraction water | 15 kg/hr |
| | • angle | 7.0° |
| | • cycle time | 17 sec |
| | • TF time forward | 9.5 sec |
| | • TR time reverse | 7.2 sec |
| 20 | • RPM | 3 |
| | • Temperature at recycle | 75°C |
| | • Residence time | 60 minutes |
| | • Preparation | Hand slicing |
| | • Pool level | Low |

25

Albedo tissue was fed to the CCE in 1 kg quantities at 5 minute intervals

- The CCE was set up at a steep angle (7°) providing sufficient head to overcome the low porosity of the bed and the high viscosity of the extracted liquid. Relatively high
- 30 temperatures were employed to minimise oxidative damage.

Fibre Handling

- The extracted fibre emerging from the CCE was pressed with partial return of press liquor to increase the level of colour, then held for a period of about 2 hours at ambient
- 35 temperature. Cleaned fibre was packed in heavy duty plastic bags in approximately 10 kg quantities with maximum thickness of 6cm. These packages were then stored at -18°C.

The fibre produced was of very pale yellow colour and mild bitterness but low in flavour and aroma. A small section of this was dried to constant weight in an oven at 110°C. During this operation some maillard browning occurred although this was not severe and is not seen as a major barrier to commercialisation .

5

Juice

Yield of soluble solids in juice 75%. This yield was deliberately set as it is known that the partition coefficient for say limonin and naringin (bitter principals) between cellulose and orange juices is about 9. With higher yields of solubles unacceptable levels of bitter
10 principals are extracted in the juice. However at a yield of 75% solubles, more than 50% of the bitter principle is carried out with the fibre.

The resultant juice was very bright but whiter in colour when compared to the spectrum of normal commercial orange products. The level of cloud was high. The juice had a
15 viscosity of 18 cp at 12° brix and normal orange juice "mouthfeel". The juice was of good aroma and flavour with high sugar acid ratio (30:1)

PREPARATION OF CARROT AND GRAPE FIBRE EXTRACTS

The fibre extracts were prepared according to the method outlined above for the
20 preparation of apple fibre extract.

PREPARATION OF GRAPEFRUIT FIBRE EXTRACT

The grapefruit fibre extract was prepared using the method set out above for preparation of orange fibre extract.

25

PREPARATION OF CRANBERRY FIBRE EXTRACT

Cranberry fibre extract is available commercially and is prepared by Ocean Spray International (Tomah, Wisconsin, USA). This extract is prepared as per the procedure outlined above except that the fibre product is reinfused with cranberry juice and marketed
30 as sweetened dried cranberries.

COMPOSITIONAL ANALYSIS OF FIBRE EXTRACTS OR PRECURSOR FRUIT

Fibre or precursor samples were frozen until analysis. When thawed, the solids were reconstituted with juice and a homogeneous sub-sample was taken and stored at 4°C until
35 samples were taken for analyses two hours later. A representative sample was freeze dried at between 5 and 6 millibars and at a temperature of -70°C to obtain dry matter for subsequent analyses. Following lyophilisation, the samples were milled to a mesh size of

0.5mm. Analyses (apart from viscosity) were performed on dried and milled samples. Data for selected fruits and vegetables is shown in Table 1.

Analyses were performed as per the following methods, all of which are known in the art.

5	Dry Matter	Lyophilised residue
	Fat (Ether Extractables)	Ether extract: AOAC 920.39
	Ash	Residue from 480°C furnace
	Viscosity at a shear rate of 200 sec ⁻¹	Cone and Plate Method
	Simple Sugars and Oligosaccharides	HPLC Method
10	Neutral Non Starch Polysaccharides	GC Uppsala Method
	Soluble and Insoluble Uronic Acids	Dubois/Scott Method
	Lignin	AOAC Official Method 994.13

PIG FEEDING TRIALS OF FIBRE EXTRACTS

15 *Materials and Methods*

Animals

A total of 28 young-adult male pigs (starting live weight = 32 kg) were chosen for experiment and maintained in individual pens with a concrete floor in a temperature-controlled room at the Pig Nutrition Research Facility (Roseworthy Campus). Pigs were obtained from the commercial piggery at the same institution.

Diets

Composition of the diets is shown in Table 2. The basal (Control) diet was formulated to be high in saturated fat (15% lipid by weight - 13% palm oil and 2% safflower oil), and marginal in calcium content (0.4%, by weight). Wheat bran was the source of dietary fibre (17% by weight, equivalent to 7.5% NSP). For treatment diets wheat bran was replaced by fibre extracts of Apple, Orange or Apple+Orange (in equal amounts)(see Table 2). Formulation of treatment diets was based on results of analyses for total dietary fibre of the two fibre extracts. Pigs were fed twice daily, at 0900 and 1600, at a rate proportional to their metabolic live weight (70 g x LW^{0.75}). The daily allowance was adjusted weekly when the animals were weighed. Pigs had unrestricted access to water for the duration of study.

35 *Surgical Preparation and Experimental Design*

For logistical reasons the study was split into two staggered sub-experiments (7-day overlap).

During the pre-experimental period, pigs were maintained on their regular commercial, pelleted diet for several days, until surgical implantation of a cephalic vein catheter. Pigs were then divided, on the basis of live weight, into 4 groups of six animals each. The remaining four animals were used as reserves. Immediately after surgery pigs were transferred to the Control diet (Day 7). After a further 7 days, three of the groups were randomly assigned to experimental diets, while the fourth group (and the unassigned animals) continued to be fed Control diet. Diets were fed for the remaining 21 days of experiment (days 7 to 28) and, at the end of the feeding period, pigs were anaesthetised in order to allow the designated samples to be collected, and then slaughtered.

Experimental Procedure and Measurements

Catheters were maintained by daily flushing of the dead-space with heparinised saline. Fasting blood samples were taken on 5 occasions (days 1, 7, 14, 21, and 28). The blood sample on Day 28 was taken from the abdominal aorta; all other blood samples were via cephalic vein catheter.

At the completion of the feeding period (day 28, - 21 days after the introduction of treatment diets) and approximately 16 hours after the pigs had been fed the evening before, they were weighed and anaesthetised (intravenous infusion of Pentothal). The abdominal cavity was opened and blood collected from the abdominal aorta, and the GI tract was then ligated and excised, along with the liver. The liver was blot-dried and weighed, and a sample collected and snap-frozen. The small and large bowels were isolated and measured. The colon was divided into three segments of equal length, and the content of each of those segments, and that of the caecum, were extruded, weighed and sub sampled. The colon and caecum, devoid of contents, were blotted dry and weighed.

Small samples of liver and plasma were analysed for cholesterol content using gas chromatography. Digesta was diluted with distilled water for determination of pH and dry matter by standard techniques, and short-chain fatty acids (SCFA), caecal bile acids and neutral sterols by GC procedures.

Data Analysis

Data are shown as the mean and pooled standard error of the mean (SEM), with the number of observations per group as indicated in the tables. Statistical analysis was by one-way analysis - variance (ANOVA) and when significant values were detected (F value $P < 0.05$), differences between individual means were then analysed by the PDIFF procedure of SAS. Differences between treatment means are considered significant at

$P < 0.05$. For tabulated results, values within a column with different superscripts differ significantly.

Hepatic and digesta metabolite pools were calculated as:

5

$$\text{Concentration } (\mu\text{mol/g or mmol/L}) \times \frac{\text{weight of liver (g), or}}{\text{volume of digesta water (mL)}}.$$

Results

10

Animal Health

During the pre-experimental period it was necessary to substitute a pig that had become lame for one from the reserve group. The catheters of two pigs in the Apple group ceased to function on about day 14 of the trial and therefore two additional pigs from the reserve group were assigned to this treatment. Consequently, at the time of slaughter, these two animals had been fed the treatment diet for just 14 days. However, as the results for these two animals were not substantially different from others in the group, they were therefore included in subsequent statistical analyses. One pig from the Apple+Orange group was euthanased just prior to completion of the study for reasons of illness (apparently unrelated to diet). During intubation (for catheterisation), several pigs were found to have a throat infection, however this appeared to be a minor ailment and did not affect food consumption or rate of growth,

15

20

Food Acceptability and Live Weight Gain

25

Pigs found the diets acceptable, and there were no indications of overt adverse reactions. Pig growth rate (and feed conversion efficiency) during the period of study was satisfactory (average daily gain was ~500 g/d), and within the range encountered in commercial piggeries. Diet had no significant effect on live weight change during the feeding period (Table 3). The growth rate data is confirmation that there were no serious adverse reactions (eg diarrhoea, gastrointestinal disturbances or nutritional deficiencies) to these diets.

30

Small and Large Bowel Morphology

Neither intestinal length nor mass were influenced by dietary treatments (Table 4). Caecal and colonic weight were greatest in pigs fed Apple+Orange, however the differences were not statistically significant. Also, there were no differences between treatments for weight of the individual colonic segments (data not shown).

35

The Apple+Orange diet may have had a stimulatory effect on intestinal growth, as intestinal mass of the small bowel, caecum and colon were each greater numerically than that of any other treatment (but statistically not significant). Given that the colon of this group was about 10% heavier, and slightly shorter in length, than that of the others, it would suggest that the mixed fibre diet may have resulted in a thickening of the colonic wall. It is worth noting that the mixed fibre diet was particularly effective in raising SCFA levels at various sites in the large bowel (see later). These metabolites are potent trophic agents for intestinal mucosa.

10 *Large Bowel Digesta Mass and Water Content*

Generally, digesta mass was similar for the four groups (Table 5). Digesta mass of pigs fed wheat bran was greater at each of the large bowel sampling sites, however, these differences reached statistical significance for the mid colon only. Digesta moisture content declined progressively from the caecum through to the distal colon (Table 6). There were no significant treatment differences for this variable in the caecum and proximal colon, however, in the mid colon, water content of digesta in pigs fed Wheat bran was greater than that of the Apple treatment, but not significantly, compared to other treatments. Digesta in the distal colon of pigs given wheat bran contained about 10% more water than that for any of the other dietary treatments.

20 Similar amounts of wet digesta mass in the caecum of each group suggests that the amount of material entering the large bowel, which is primarily non-absorbed carbohydrate, is similar. For the Wheat bran group, there appears to be a progressive loss of material along the colon, however, for fibre extract treatments, fermentation occurs mainly in the proximal and mid colon. This finding reflects and confirms the highly fermentable nature of the fibre extract products. As large bowel bacteria catabolise fibre, its structure, and hence, water- holding capacity diminishes, along with the contribution that these materials could make to digesta mass and, hence, faecal weight. Although the fibre extracts would be expected to promote growth of enteric bacteria, this activity would occur primarily in the proximal region of the large bowel, and the contribution of expanded bacterial biomass to stool output may not be large. Data for the large bowel is compatible with the finding that the faeces of pigs fed diets containing fibre extracts, compared to Wheat bran, were much firmer, and formed into dense pellets. The apparent "constipating" effects of the fibre extract diets, however, do not appear to have been particularly serious (food intake, for example, was not compromised). Earlier studies have indicated that the optimal water content in digesta and faeces is 70- 80%. Also, because wheat bran is the most effective dietary fibre source for promoting stool weight (and alleviating constipation in human), differences with other fibres in relation to faecal output and consistency are expected.

Large Bowel pH

At each of the intestinal sampling sites, acidic conditions were found in large bowel lumen of those pigs receiving fibre extracts, compared to the Wheat bran. Differences in pH for the individual fibre extract treatments (Table 7) were not significant.

The fermentability of fibre extracts is clearly reflected in the acidic conditions found in the large bowel, especially in the caecum, and to a lesser extent, in the colon. Acidification of luminal contents has desirable health consequences, in that the formation, availability and absorption of various carcinogens and toxic materials in the hindgut is reduced. Indeed, a high pH in the human large bowel is thought to be a risk factor for colorectal cancer.

Large Bowel Short Chain Fatty Acid Concentrations

Generally, concentrations of total SCFA tended to be greatest in the caecum and proximal colon compared to the other sites, and throughout the large bowel, levels of these metabolites were higher in pigs fed fibre extracts (particularly for the diet containing mixed fibres) relative to Wheat bran, although only a few differences reached statistical significance (Table 8). Profiles for each of the individual SCFA were similar (Table 9-11). Compared to Wheat bran, the Apple+Orange treatment produced substantially higher butyrate concentrations in the proximal and distal colon. Total and individual SCFA values for the mixed fibre treatment were (numerically) greater than those values obtained for either Apple or Orange fibre.

The finding that fibre extracts were effective in raising SCFA level is significant because of the purportive role of these metabolites in the prevention and amelioration of important large bowel diseases. The mixed fibre diet was particularly effective in raising butyrate levels throughout the large bowel, especially in the distal colon, which is the site of most bowel disease in humans. The extent to which the level of SCFA and in particular butyrate has increased is quite surprising and is indicative of a synergy that has taken place between the fibre extracts. The exact nature of the synergy is unknown but it is expected that the synergy will also take place between fibre extracts of other fruit and vegetable sources. The effect of continued consumption of the mixed fibre product however is suggested to enhance the bacteria in the large intestine that are capable of producing SCFA and thereby reducing the population of bacteria that lead to adverse health effects.

The fibre extracts used are convenient to handle because they are fermentable in the large bowel, and are not heat labile.

It is thought that the high pectin content of the two fibre extracts used provides a fermentable fibre but the nature of the synergy is not clear at present.

HUMAN FEEDING TRIALS OF FIBRE EXTRACTS

5 *Materials and Methods*

Subjects

The study group consisted of 23 volunteers, 12 males and 11 females, aged between 39 and 70 years (mean SEM 51.3 ± 1.8 y) and BMI 24.26 ± 0.49 kg/m².

10

Diets

The study consisted of a balanced, two-period crossover trial preceded by a baseline (reference) period. Subjects were randomly allocated to either the Wheat bran cereal or the test cereal (PTI fibre) supplement group for 14 days and then assigned to the alternative dietary supplement for the same period of time.

15

The two dietary supplements were extruded breakfast cereals prepared from digestible starch and either Wheat bran or an orange and apple fibre extract (PTI fibre) as the test fibre. Volunteers were provided with 34 or 45 g daily portions of PTI or Wheat bran cereal, respectively, equivalent to approximately 15 g of dietary fibre. They were asked to consume daily the respective supplements for each of the 2-week intervention periods. Fibre intake was restricted to about 20 g/day during the Baseline (pre-supplementation) period by providing subjects with a low fibre cereal and advising them to avoid designated high fibre foods which they also refrained from eating throughout the study.

20

25

Experimental Procedure and Measurements

Stools were collected over a 48-hour period prior to (Baseline) and 2 weeks after commencing each intervention. Faecal specimens were weighed, mixed thoroughly before a subsample of approximately 1 g was taken for estimation of water content. A further subsample of faeces was diluted with a known volume of internal standard, for SCFA determination, and the pH of the slurry determined by insertion of an appropriate electrode. Total and major individual short-chain fatty acid concentrations were measured by gas chromatography.

30

35 *Data Analysis*

Faecal data were analysed as a randomised complete block design by two-way analysis of variance using the General Linear Model procedure of Statistical Analytical Systems. Gender was used as the block. Differences between baseline and dietary treatments were

determined using the protected difference procedure of SAS. Results are presented as least squares means and their pooled standard error (SEM).

Results

5 Large Bowel pH

Acidic conditions were found in faecal samples before and after receiving fibre extracts (Tables 12, 13). Differences in pH for the extract treatments and the Wheat bran treatment were not significant.

10 Large Bowel Short Chain Fatty Acid Concentrations

Generally, concentrations of total SCFA tended to higher in subjects fed fibre extracts relative to Wheat bran (Tables 14-17). Profiles for each of the individual SCFA were similar (Tables 14-17).

15 FORMULATIONS CONTAINING FIBRE EXTRACTS

Breakfast cereal

An example of a food product to which the apple and orange fibre mix, in the proportions set out above might be added is set out below.

20

A breakfast cereal formulation is as follows:

	Normal	With fibre mixture
Maize flour	91%	77%
Fibre mixture -		14%
25 Malt	3%	3%
Sugar	5%	5%
Salt	1%	1%

30 The process of making the corn flake product with fibre mixture is the same as making the cornflake mixture with the normal mix and is in accordance with methods known to the person skilled in the art.

An example of a breakfast cereal to which the carrot and grape fibre mix might be added is as follows:

35

Carrot fibre	16%
Grape fibre	16%
Wheat or cornflour	21%

Wheat bran	19%
Malt	10%
Sugar	17.2%
Salt	0.8%

5

An example of a breakfast cereal to which the cranberry and grapefruit fibre mix might be added is as follows:

	Cranberry fibre	19%
10	Grapefruit fibre	13%
	Wheat or cornflour	21%
	Wheat bran	19%
	Malt	10%
	Sugar	17.2%
15	Salt	0.8%

An example of a granola to which the apple and orange fibre mix might be added is as follows:

20	Rolled oats	30%
	Apple fibre	16%
	Orange fibre	15%
	Crisped Rice	11%
	Almonds	8%
25	Coconut	8%
	Gum Arabic	5%
	Gum Ghatti	4%
	Guar Gum	3%

30 An example of a fruit juice to which the apple and orange fibre mix might be added is a commercial orange juice (98% juice) to which 3% by weight of the fibre mix is added.

An example of a soup to which the carrot and grape fibre mix might be added is a commercial vegetable soup mix containing vegetables, meat stock and starch to which is added 8% by weight of the fibre mix.

35

Various features of the invention have been particularly shown and described in connection with the exemplified embodiment of the invention, however, it must be understood that

these particular arrangements merely illustrate and that the invention is not limited thereto and can include various modifications falling within the spirit and scope of the invention.

ART 34 AMDT

21

CLAIMS

1. A food supplement, said food supplement derived from fibre extracts from two or more types of fruit or vegetables, the fibre extracts having had a majority of soluble solids removed therefrom.
2. A food supplement according to claim 1 wherein greater than 90% of soluble solids are removed.
3. A food supplement according to claim 2 wherein from between 93 to 99% of soluble solids are removed.
4. A food supplement according to claim 1 wherein a first of the two or more types of fruit or vegetables is selected from the group consisting of citrus, tomato, carrot, mango, papaya, banana, pineapple, kiwi fruit, spinach and a second of the two or more types of fruit or vegetables is selected from the group consisting of melon, grape, apple and cranberry.
5. A food supplement according to claim 4 wherein the melon is selected from the group consisting of watermelon, rock melon, honeydew melon or champagne melon.
6. A food supplement according to claim 4 wherein the first of the two or more fruit and vegetables is a citrus fruit or carrot and the second of the two or more fruit or vegetables is selected from the group consisting of grape, apple and cranberry.
7. A food supplement according to claim 6 wherein the first of the two or more types of fruit or vegetables is selected from the group consisting of orange, carrot and grapefruit and the second of the two or more types of fruit or vegetables is selected from the group consisting of grape, apple and cranberry.
8. A food supplement according to claim 1 wherein a first of the two or more fruits or vegetables has a calcium content of between 4000 and 15000 ppm and a second of the two or more fruit or vegetables has a calcium content of between 200 and 1500 ppm.
9. A food supplement according to claim 1 wherein a first of the two or more fruits or vegetables has a soluble neutral non starch polysaccharide content of between 2 and 3 percent dry weight and a second of the two or more fruit or vegetables has a soluble neutral non starch polysaccharides content of between 1 and 2 percent dry weight.

10. A food supplement according to claim 1 wherein a first of the two or more fruits or vegetables has a total uronic acids content of between 20 and 40 percent dry weight and a second of the two or more fruit or vegetables has a total uronic acids content of between 5 and 20 percent dry weight.

11. A food supplement according to claim 1 wherein the first of the two or more fruits or vegetables has :
a calcium content of between 4000 and 15000 ppm;
a soluble neutral non starch polysaccharides content of between 2 and 3 percent dry weight; and
a total uronic acids content of between 20 and 40 percent dry weight
and the second of the two or more fruit or vegetables has :
a calcium content of between 200 and 1500 ppm;
a soluble neutral non starch polysaccharides content of between 1 and 2 percent dry weight; and
a total uronic acids content of between 5 and 20 percent dry weight.

12. A food supplement according to claim 11 wherein the first of the two or more fruit and vegetables is an orange, and the second of the two or more fruit or vegetables is selected from the group consisting of apple, grape and cranberry.

13. A food supplement according to claim 12 wherein the first of the two or more fruit and vegetables is an orange and the second of the two or more fruit or vegetables is an apple.

14. A food supplement according to claim 11 wherein the first of the two or more fruit and vegetables is a carrot, and the second of the two or more fruit or vegetables is selected from the group consisting of apple, grape and cranberry.

15. A food supplement according to claim 14 wherein the first of the two or more fruit and vegetables is a carrot, and the second of the two or more fruit or vegetables is a grape.

16. A food supplement according to claim 11 wherein the first of the two or more fruit and vegetables is a grapefruit, and the second of the two or more fruit or vegetables is selected from the group consisting of apple, grape and cranberry.

ART 34 AMDT

17. A food supplement according to claim 16 wherein the first of the two or more fruit and vegetables is a grapefruit, and the second of the two or more fruit or vegetables is a cranberry.
18. A food product having the food supplement of any one of claims 1 to 17.
19. A food product according to claim 18 wherein the food product contains between 1 and 50 % by weight of the food supplement.
20. A food product according to claim 19 wherein the food product contains between 1 and 30% by weight of the food supplement.
21. A food product according to claim 20 wherein the food product is a breakfast cereal.
22. A food product according to claim 20 wherein the food product is a granola bar.
23. A food product according to claim 20 wherein the food product is a soup that contains between 2 and 15% of the food supplement.
24. A food product according to claim 20 wherein the food product is a beverage that contains between 2 and 5 % of the food supplement.
25. A method of preparing a food supplement derived from fibre extracts from two or more types of fruit or vegetables, the method including the steps of removing a majority of the soluble solids from each of the two or more types of fruit or vegetables separately to give fibre extracts from the two or more fruits or vegetables, and combining the fibre extracts to provide the food supplement.
26. A method of preparing a food supplement according to claim 25 wherein greater than 90% of soluble solids are removed.
27. A method of preparing a food supplement according to claim 26 wherein from between 93 to 99% of soluble solids are removed.
28. A method of preparing a food supplement according to one of claims 25 or 27 wherein each of the two or more fruits or vegetables is sliced so as to substantially minimise breakdown of the structure of macromolecules forming the fibres.

ART 34 AMDT

29. A method of preparing a food supplement according to claim 26 wherein the method includes the step of inactivating enzymes within the fruit or vegetables.
- 5 30. A method of preparing a food supplement according to claim 29 wherein the step of inactivating enzymes is by heat inactivation.
31. A method of preparing a food supplement according to claim 30 wherein the majority of soluble solids are removed by liquid extraction.
- 10 32. A method of preparing a food supplement according to claim 31 wherein the extraction liquid is selected from the group consisting of water, chloroform, hexane, chlorinated hydrocarbons, acetone or ethanol.
- 15 33. A method of preparing a food supplement according to claim 32 wherein the extraction liquid is water.
34. An agent for increasing levels of one or more fatty acids to the colon of an animal or human, said agent derived from fibre extracts from two or more types of fruit or
20 vegetables, the fibre extracts having had a majority of soluble solids removed therefrom.
35. An agent for increasing levels of one or more fatty acids to the colon of an animal or human according to claim 34 wherein the increase in levels of fatty acid in the colon is greater than the level afforded by any one of the fruits or vegetables alone.
- 25 36. An agent for increasing levels of one or more fatty acids to the colon of an animal or human according to claim 35 wherein the fatty acid is a short chain fatty acid.
37. An agent for increasing levels of one or more fatty acids to the colon of an animal or human according to claim 36 wherein a first of the two or more types of fruit or
30 vegetables is selected from the group consisting of citrus, tomato, carrot, mango, papaya, banana, pineapple, kiwi fruit, spinach and a second of the two or more types of fruit or vegetables is selected from the group consisting of melon, grape, apple and cranberry.
- 35 38. An agent for increasing levels of one or more fatty acids to the colon of an animal or human according to claim 37 wherein the first of the two or more fruit and vegetables is a citrus fruit or carrot and the second of the two or more fruit or vegetables is selected from the group consisting of grape, apple and cranberry.

ART 34 AMDT

39. An agent for increasing levels of one or more fatty acids to the colon of an animal or human according to claim 38 wherein the first of the two or more types of fruit or vegetables is selected from the group consisting of orange, carrot and grapefruit and the
- 5 second of the two or more types of fruit or vegetables is selected from the group consisting of grape, apple and cranberry.

TABLE 1
Relative compositions of selected fruits and vegetables

Component	Fruit 1			Fruit 2		
	Apple	Grape	Cranberry	Orange	Grapefruit	Carrot
Calcium (ppm)	1434	500-1000	319	10071	10000	4309
Potassium (ppm)	3518	7000	1750	1821	1800	7794
Soluble NNSP (% dry wt.)	1.43	1.30	1.5	2.23	2.25	2.19
Total NNSP (% dry wt.)	29.91	29-30	30.0	29.98	30.0	29.17
Soluble uronics (% dry wt.)	10.0	5.0	5.0	14.0	14.0	6.7
Total uronics (% dry wt.)	16.8	9.0	10.0	31.9	32.0	21.1
Lignin (% dry wt.)	24.0	24.0	24.0	25.0	25.0	18.6

TABLE 2
Composition of experimental diets (g/kg)

Ingredient	Control	Apple	Orange	Apple+Orange
Casein	160	143	144	143
Starch	497	497	497	497
Sugar	100	53	58	55
Palm oil	130	188	188	188
Safflower oil	20	20	20	20
Wheat bran	75	-	-	-
Apple extract	-	106	-	53
Orange extract	-	13.3	96	48
Dicalcium phosphate	13.3	13.3	13.3	13.3
Minerals (other)	3.2	3.2	3.2	3.2
Vitamins	1.5	1.5	1.5	1.5

TABLE 3
Initial and final live weight, and live weight gain of pigs

Dietary group	Live Weight		Live Weight Gain
	Initial	Final	
		kg	
Wheat bran	31.6	48.1	16.5
Apple	31.8	46.1	14.2
Orange	33.2	47.8	14.6
Apple+Orange	33.5	48.7	15.2
SEM	1.3	1.8	1.0

Values are means for 7, 8, 6 and 5 observations for treatments Wheat bran, Apple, Orange and Apple+Orange, respectively. Treatment differences are not statistically significant ($P < 0.05$).

TABLE 4
Morphology of the small and large bowel

Dietary group	Small Intestine		Caecum		Colon	
	Length	Weight	Length	Weight	Length	Weight
	m	g	cm	g	m	g
Wheat bran	15.29	95.9	16.7	568	2.97	
Apple	15.15	101.5	15.6	550	2.84	
Orange	14.65	89.7	14.8	547	2.81	
Apple+Orange	15.32	109.8	15.2	613	2.77	
SEM	0.51	9.4	1.0	34	0.12	

Values are means, with number of observations as per Table 5.

TABLE 5
Wet weight of digesta in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon	Distal colon	Total colon
			g		
Wheat bran	152	349	216 ^a	154	871
Apple	135	252	117 ^c	107	611
Orange	169	274	118 ^b	81	642
Apple+Orange	143	243	129 ^b	112	627
SEM	37	39	27	22	90

Values are means, with number of observations as per Table 2. Means in the same column with different superscript letters differ ($P < 0.05$). a-b, $P < 0.05$, a-c, $P < 0.01$.

TABLE 6
Water content of digesta in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon %	Distal colon
Wheat bran	88	84.4	79.8 ^a	73.2 ^a
Apple	90.4	83.6	74.5 ^b	63.2 ^c
Orange	88.4	82.1	76.5	63.9 ^c
Apple+Orange	91.0	84.0	76.0	62.8 ^c
SEM	2.1	2.0	2.0	2.0

Values are means, with number of observations as per Table 5. Means in the same column with different superscript letters differ a-b, $P<0.05$; a-c, $P<0.01$.

TABLE 7
pH of digesta in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon	Distal colon
Wheat bran	7.13 ^a	7.10 ^a	7.21 ^a	7.09 ^a
Apple	5.84 ^d	6.18 ^d	6.24 ^d	6.29 ^d
Orange	5.84 ^d	6.09 ^d	6.14 ^d	6.28 ^d
Apple+Orange	5.85 ^d	6.06 ^d	6.06 ^d	6.05 ^d
SEM	0.16	0.11	0.13	0.13

Values are means, with number of observations as per Table 2. Means in the same column with different superscript letters differ a-b, $P<0.05$; a-c, $P<0.01$, a-d, $P<0.01$.

TABLE 8
Concentration of total SCFA in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon	Distal colon
	mmol/L			
Wheat bran	62.8	60.5 ^a	53.1	55.4
Apple	68.3	71.1 ^a	55.4	43.7
Orange	75.5	79.9 ^{ac}	67.6	42.5
Apple+Orange	88.2	93.3 ^c	76.3	61.7
SEM	15.7	7.3	8.3	6.7

Values are means, with number of observations as per Table 2. Means in the same column with different superscript letters differ: a-c, $P < 0.01$. For the Proximal colon, Wheat bran vs Orange, $P = 0.07$; for Mid colon and Distal colon, ANOVA F value not significant. For Mid colon, Wheat bran vs Apple+Orange, $P = 0.073$; Apple vs Apple+Orange, $P = 0.095$. For Distal colon, Apple+Orange vs Apple, $P = 0.074$, Apple+Orange vs Orange, $P = 0.074$.

TABLE 9
Concentration of total acetate in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon	Distal colon
	mmol/L			
Wheat bran	40.8	38.6 ^a	33.7	35.2
Apple	43.0	42.4 ^{bc}	33.3	27.0
Orange	48.6	48.5	39.6	26.6
Apple+Orange	59.2	60.1 ^c	46.2	36.7
SEM	10.2	4.8	5.3	4.2

Values are means, with number of observations as per Table 2.

Means in the same column with different superscript letters differ: a-b, $P < 0.05$; a-c, $P < 0.01$.

TABLE 10
Concentration of propionate in the large bowel

Dietary Group	Caecal	Proximal colon	Mid colon	Distal colon
	mmol/L			
Wheat bran	17.3	15.7	12.0	12.6
Apple	19.5	19.6	12.9	8.38
Orange	21.2	22.6	18.1	8.73
Apple+Orange	21.2	22.7	19.1	11.9
SEM	4.4	2.3	2.7	1.7

Values are means, with number of observations as per Table 2.
ANOVA F value not significant.
For Mid colon, Wheat bran vs Apple+Orange, $P=0.085$.
For Distal colon, Wheat bran vs Apple, $P=0.076$.

TABLE 11
Concentration of butyrate in the large bowel

Dietary Group	Caecal	mmol/L		
		Proximal colon	Mid colon	Distal colon
Wheat bran	4.74	6.06	7.43	7.67 ^a
Apple	5.83	9.15	9.20	8.28 ^a
Orange	5.73	8.80	9.90	7.13 ^a
Apple+Orange	7.80	10.4	11.0	13.0 ^b
SEM	1.62	1.1	1.4	1.4

Values are means, with number of observations as per Table 2. Means in the same column with different superscript letters differ: ANOVA F value not significant for Caecum, Proximal and Mid colon. For Proximal colon, Wheat bran vs Apple, $P=0.052$.

TABLE 12
Faecal pH, moisture content, and wet and dry weight in volunteers before and after dietary supplementation¹

Period & Measurement ²	Dietary Treatment		Pooled sem ³
	Baseline	Fruit-fibre product Wheat bran cereal	
pH	6.91	6.76	6.81
			0.10
Wet weight (g)	260a	337b	347b
			25
Moisture content (%)	26.7	25.1	25.7
			1.3
Dry weight (g)	64.9a	79.5b	85.4b
			5.2

¹Data were analysed as completely randomised design using analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 23 observations.

²Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment.

³Pooled standard error of least squares means (SEM).

a-bP<0.05. For faecal dry weight, Baseline vs Wheat bran, P = 0.007.

TABLE 13

Period & Measurement2		Dietary Treatment			Pooled sem3
		Baseline	Fruit fibre product	Wheat bran cereal	
pH	Male	6.96	6.74	6.70	0.14
	Female	6.85	6.79	6.92	0.15
Wet weight (g)	Male	296a	416b	408b	36
	Female	225	258	286	35
Moisture content (%)	Male	23.5	23.5	24.6	1.8
	Female	29.9	26.6	26.7	1.9
Dry weight (g)	Male	68a	95b	100b	7
	Female	61	64	71	7

Data were analysed as completely randomised design using two-way analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 12 female and 13 male volunteers.

2 Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment.

33 Pooled standard error of least squares means (SEM).

TABLE 14
Faecal short chain fatty acid (SCFA) concentrations and molar ratios before (Baseline) and after dietary supplementation¹

Period & Measurement2	Dietary Treatment		Pooled sem3
	Baseline	Fruit-fibre product	
	Faecal SCFA concentration (mM)		
Acetate	47.4	58.5	51.1
Propionate	13.5	15.7	13.5
Butyrate	16.7	19.9	17.9
Total SCFA	77.6	94.1	82.4
SCFA molar ratio (A:P:B)4	61:18:22	63:17:20	63:17:20
			-

†Data were analysed as completely randomised design using analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 23 observations.

22 Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment.

33 Pooled standard error of least squares means (SEM).

TABLE 15
Faecal short chain fatty acid (SCFA) concentrations and molar ratios weight in male and female volunteers before (Baseline) and after dietary supplementation¹

Period & Measurement ²	Dietary Treatment		Pooled sem ³
	Baseline	Fruit fibre product Wheat bran cereal	
Faecal SCFA concentration (mM)			
Acetate	42.2a	61.6b	53.8
	52.7	55.5	48.5
Propionate	12.7	17.0	13.9
	14.7	14.3	13.0
Butyrate	16.2	17.3	16.6
	17.2	22.5	19.1
Total SCFA	72.0	101.1	86.8
	83.3	87.1	78.0
SCFA molar ratio (A:P:B) ⁴	58:19:24	61:17:22	62:17:21
	64:17:19	65:17:18	64:17:20
			11.3
			11.8
			-
			-

¹Data were analysed as completely randomised design using two-way analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 12 female and 13 male volunteers. ²Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment. ³Pooled standard error of least squares means (SEM). For propionate concentration: Baseline vs PTI product, P = 0.103 for male volunteers. For total SCFA concentration: Baseline vs PTI product, P = 0.073 for male volunteers.

TABLE 16
Faecal short chain fatty acid (SCFA) excretion in volunteers before (Baseline) and after dietary treatments¹

Period & Measurement ²	Dietary Treatment		Pooled sem ³
	Baseline	Fruit fibre product	
Faecal SCFA excretion (mmol)			
Acetate	9.91a	16.44b	2.10
Propionate	2.85	4.36	0.56
Butyrate	3.63	5.89	0.97
Total SCFA	16.38a	26.69b	3.54

¹Data were analysed as completely randomised design using analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 23.

²Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment

³Pooled standard error of least squares means (SEM).

a-bP<0.05. For propionate and butyrate excretion: Baseline vs PTI product, P = 0.060 and 0.105, respectively.

TABLE 17
Faecal short chain fatty acid (SCFA) excretion in male and female volunteers before (Baseline) and after dietary treatments¹

Period & Measurement ²	Dietary Treatment			Pooled sem ³
	Baseline	Fruit fibre product	Wheat bran cereal	
Faecal SCFA excretion (mmol)				
Acetate				
Male	10.11a	21.02b	16.82	2.91
Female	9.70	11.86	11.38	3.04
Propionate				
Male	3.02a	5.62b	4.38	0.77
Female	2.68	3.10	3.06	0.81
Butyrate				
Male	4.36	8.15	6.24	1.35
Female	2.90	3.64	4.02	1.41
Total SCFA				
Male	17.48a	34.79b	27.45	4.89
Female	15.29	18.59	18.46	5.11

¹Data were analysed as completely randomised design using two-way analysis of variance. Means separation was by protected difference option of SAS. Values are least squares means for 23.

²Faecal samples were collected over two consecutive days immediately prior to (Baseline) and after 4 weeks of dietary treatment.

³Pooled standard error of least squares means (SEM).

a-bP<0.05.

For butyrate excretion: Baseline vs PT1 product, P = 0.051 for male volunteers.

**COMBINED DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES
PATENT APPLICATION**

As a below named inventor, we hereby declare that:

My residence, post office address and citizenship are the same as stated below next to my name.

We believe we are an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:-

Food Supplement

the specification of which

☐

is attached hereto

☒

was filed as PCT International application No. PCT/AU99/00273 on 14th April 1999 and was amended on 11th November 1999

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information known to us to be material to the examination of this application in accordance with Title 37, Code of Federal Regulations, S1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, S119 of any foreign application for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the applicant on which priority is claimed.

Number	Country	Filing Date (d/m/y)	Priority Claimed
PP2915	Australia	14th April 1998	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no

We hereby claim the benefit under Title 35, United States Code, S120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by



15-06-2009

the first paragraph of Title 35, United States Code, S112, we acknowledge the duty to disclose all information known to us to be material to patentability as defined in Title 37, Code of Federal Regulation, S1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No. Filing Date (d/m/y) Status (Patented, Pending, Abandoned)

We hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

(2) Henry D. Coleman, Reg. No. 32,559; R. Neil Sudol, Reg. No. 31,669

Address all telephone calls to: R. Neil Sudol/Henry D. Coleman
at Telephone No. (212)6790090

Address all correspondence to: R. Neil Sudol/Henry D. Coleman
at Coleman Sudol, LLP
708 Third Avenue 14th Floor
NEW YORK NEW YORK 10017-4104
UNITED STATES OF AMERICA

We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor:- Timothy LANG

Residence: Level 3, 71 Archer Street, Chatswood, New South Wales 2067, Australia

Post Office Address: as above

Country of Citizenship AUSTRALIA

Date

11th September 2000

Timothy LANG

200
Full name of second inventor:-

Derek DENTON

Residence: 816 Orrong Road, Toorak, Victoria 3142, Australia

Post Office Address: as above

Country of Citizenship AUSTRALIA

25/8/2000
Date

Derek Denton
Derek DENTON

300
Full name of third inventor:- Anthony R BIRD

Residence: Kintore Avenue, Adelaide, South Australia 5000, Australia

Post Office Address: as above

Country of Citizenship AUSTRALIA

12/8/00
Date

Anthony R Bird
Anthony R BIRD

400
Full name of fourth inventor:- David TOPPING

Residence: Kintore Avenue, Adelaide, South Australia 5000, Australia

Post Office Address: as above

Country of Citizenship AUSTRALIA

17/8/2000
Date

David Topping
David TOPPING